{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:40:25Z","timestamp":1793932825071,"version":"4.8.0"},"reference-count":208,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.jtos.2017.05.009","type":"journal-article","created":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T15:59:20Z","timestamp":1500566360000},"page":"629-649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":123,"title":["TFOS DEWS II Clinical Trial Design Report"],"prefix":"10.1016","volume":"15","author":[{"given":"Gary D.","family":"Novack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny","family":"Asbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Barabino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael V.W.","family":"Bergamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph B.","family":"Ciolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary N.","family":"Foulks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Lemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schrader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Stapleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtos.2017.05.009_bib1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1542-0124(12)70084-8","article-title":"Design and conduct of clinical trials: Report of the Clinical Trials Subcommittee of the International Dry Eye WorkShop (2007)","volume":"5","year":"2007","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2017.05.009_bib2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II Definition and Classification report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"issue":"6","key":"10.1016\/j.jtos.2017.05.009_bib3","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.jtos.2017.05.009_bib4","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials","volume":"36","author":"Felson","year":"1993","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.jtos.2017.05.009_bib5","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1097\/ICO.0b013e318242fd60","article-title":"Clinical utility of objective tests for dry eye disease: variability over time and implications for clinical trials and disease management","volume":"31","author":"Sullivan","year":"2012","journal-title":"Cornea"},{"issue":"12","key":"10.1016\/j.jtos.2017.05.009_bib6","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.1167\/iovs.10-5390","article-title":"An objective approach to dry eye disease severity","volume":"51","author":"Sullivan","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.jtos.2017.05.009_bib7","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jtos.2012.02.001","article-title":"Report of the TFOS\/ARVO Symposium on global treatments for dry eye disease: an unmet need","volume":"10","author":"Sullivan","year":"2012","journal-title":"Ocul Surf"},{"issue":"15","key":"10.1016\/j.jtos.2017.05.009_bib8","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jacc.2014.08.008","article-title":"Do current clinical trials meet Society's needs?","volume":"64","author":"Pocock","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtos.2017.05.009_bib9","doi-asserted-by":"crossref","first-page":"h1389","DOI":"10.1136\/bmj.h1389","article-title":"Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial","volume":"350","author":"van Herwaarden","year":"2015","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.jtos.2017.05.009_bib10","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1001\/jamapsychiatry.2015.0111","article-title":"Effects of estradiol withdrawal on mood in women with past perimenopausal depression: a randomized clinical trial","volume":"72","author":"Schmidt","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jtos.2017.05.009_bib11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jclinepi.2015.06.024","article-title":"An in silico approach helped to identify the best experimental design, population, and outcome for future randomized clinical trials","volume":"69","author":"Bajard","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.jtos.2017.05.009_bib12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000431289","article-title":"Randomized, double-blind, placebo-controlled, withdrawal study of colestilan after dose titration in chronic kidney disease dialysis patients with hyperphosphatemia","volume":"130","author":"Hertel","year":"2015","journal-title":"Nephron"},{"key":"10.1016\/j.jtos.2017.05.009_bib13","first-page":"25694","article-title":"International conference on harmonisation; good clinical practice: consolidated guideline; notice of availability","volume":"62","author":"Anonymous","year":"1997","journal-title":"Fed Reg"},{"key":"10.1016\/j.jtos.2017.05.009_bib14","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II Management and Therapy report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2017.05.009_bib15","series-title":"Guidance for industry CGMP for phase 1 investigational drugs","author":"Anonymous","year":"2008"},{"key":"10.1016\/j.jtos.2017.05.009_bib16","series-title":"Guidance for industry - INDs for phase 2 and phase 3 studies - chemistry, manufacturing, and controls information","author":"Anonymous","year":"2003"},{"key":"10.1016\/j.jtos.2017.05.009_bib17","series-title":"Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals","author":"ICoMJ","year":"2015"},{"key":"10.1016\/j.jtos.2017.05.009_bib18","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1136\/bmj.290.6473.1002","article-title":"Proposal to outlaw the term \u201cnegative trial","volume":"290","author":"Chalmers","year":"1985","journal-title":"BMJ"},{"key":"10.1016\/j.jtos.2017.05.009_bib19","doi-asserted-by":"crossref","first-page":"f6170","DOI":"10.1136\/bmj.f6170","article-title":"Medical journal editors and publication bias","volume":"347","author":"Brice","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jtos.2017.05.009_bib20","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1001\/jama.292.11.1363","article-title":"Clinical Trial Registration: A Statement from the International Committee of Medical Journal","volume":"292","author":"DeAngelis","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jtos.2017.05.009_bib21","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJMsa1012065","article-title":"The ClinicalTrials.gov results database\u2013update and key issues","volume":"364","author":"Zarin","year":"2011","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jtos.2017.05.009_bib22","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMc1505965","article-title":"Trial-results reporting and academic medical centers","volume":"372","author":"Zarin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtos.2017.05.009_bib23","first-page":"64982","article-title":"Clinical trials registration and results information submission","volume":"81","author":"Anonymous","year":"2016","journal-title":"Fed Reg"},{"issue":"2","key":"10.1016\/j.jtos.2017.05.009_bib24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.tig.2014.12.006","article-title":"NIH's genomic data sharing policy: timing and tradeoffs","volume":"31","author":"Contreras","year":"2015","journal-title":"Trends Genet"},{"issue":"22","key":"10.1016\/j.jtos.2017.05.009_bib25","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1056\/NEJMp1411794","article-title":"Data sharing, year 1-access to data from industry-sponsored clinical trials","volume":"371","author":"Strom","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtos.2017.05.009_bib26","doi-asserted-by":"crossref","first-page":"f2865","DOI":"10.1136\/bmj.f2865","article-title":"Restoring invisible and abandoned trials: a call for people to publish the findings","volume":"346","author":"Doshi","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jtos.2017.05.009_bib27","doi-asserted-by":"crossref","first-page":"h4629","DOI":"10.1136\/bmj.h4629","article-title":"No correction, no retraction, no apology, no comment: paroxetine trial reanalysis raises questions about institutional responsibility","volume":"351","author":"Doshi","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jtos.2017.05.009_bib28","doi-asserted-by":"crossref","first-page":"h4320","DOI":"10.1136\/bmj.h4320","article-title":"Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence","volume":"351","author":"Le Noury","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jtos.2017.05.009_bib29","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/jama.2014.10716","article-title":"Sharing and reporting the results of clinical trials","volume":"313","author":"Hudson","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jtos.2017.05.009_bib30","doi-asserted-by":"crossref","first-page":"e1001950","DOI":"10.1371\/journal.pmed.1001950","article-title":"Sharing clinical trial data: a proposal from the international committee of medical journal editors","volume":"13","author":"Taichman","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.jtos.2017.05.009_bib31","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1056\/NEJMe1601087","article-title":"Data sharing and the journal","volume":"374","author":"Drazen","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtos.2017.05.009_bib32","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1126\/science.aaf4545","article-title":"Data sharing","volume":"351","author":"McNutt","year":"2016","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jtos.2017.05.009_bib33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0969141316646604","article-title":"Sharing clinical trial data","volume":"24","author":"Wald","year":"2017","journal-title":"J Med Screen"},{"key":"10.1016\/j.jtos.2017.05.009_bib34","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1996.03540080059030","article-title":"Improving the quality of reporting of randomized controlled trials. The CONSORT statement","volume":"276","author":"Begg","year":"1996","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jtos.2017.05.009_bib35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1542-0124(12)70023-X","article-title":"The CONSORT statement for publication of controlled clinical trials","volume":"2","author":"Novack","year":"2004","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2017.05.009_bib36","series-title":"Data monitoring committees in clinical trials: a practical perspective","author":"Ellenberg","year":"2002"},{"issue":"1","key":"10.1016\/j.jtos.2017.05.009_bib37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1542-0124(12)70217-3","article-title":"Data monitoring Committees","volume":"8","author":"Novack","year":"2010","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.jtos.2017.05.009_bib38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jtos.2014.05.001","article-title":"Why aren't there more pharmacotherapies for dry eye?","volume":"12","author":"Novack","year":"2014","journal-title":"Ocul Surf"},{"issue":"2","key":"10.1016\/j.jtos.2017.05.009_bib39","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jtos.2015.11.003","article-title":"Report of the inaugural meeting of the TFOS i(2) = initiating innovation series: targeting the unmet need for dry eye treatment","volume":"14","author":"Chao","year":"2016","journal-title":"Ocul Surf"},{"issue":"5","key":"10.1016\/j.jtos.2017.05.009_bib40","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ajo.2010.10.032","article-title":"Tear osmolarity in the diagnosis and management of dry eye disease","volume":"151","author":"Lemp","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.jtos.2017.05.009_bib41","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/00003226-199811000-00002","article-title":"The pathology of dry eye: the interaction between the ocular surface and lacrimal glands","volume":"17","author":"Stern","year":"1998","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2017.05.009_bib42","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II Epidemiology report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2017.05.009_bib43","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","article-title":"TFOS DEWS II Pathophysiology report","volume":"15","author":"Bron","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2017.05.009_bib44","first-page":"3116","article-title":"Sympathetic swelling response of the control eye to soft lenses in the other eye","volume":"40","author":"Fonn","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2017.05.009_bib45","doi-asserted-by":"crossref","DOI":"10.1111\/j.1755-3768.2012.T049.x","article-title":"Lacrymal secretion in the non-affected fellow eye of patients with recurrent unilateral herpetic keratitis","volume":"90","author":"Mgarrech","year":"2012","journal-title":"Acta Ophthalmol"},{"issue":"11","key":"10.1016\/j.jtos.2017.05.009_bib46","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/ICO.0b013e3181cbf9f5","article-title":"Association between unilateral quiescent stromal herpetic keratitis and bilateral dry eyes","volume":"29","author":"Simard-Lebrun","year":"2010","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2017.05.009_bib47","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/ICO.0000000000000425","article-title":"Do unilateral herpetic stromal keratitis and neurotrophic ulcers cause bilateral dry eye?","volume":"34","author":"Jabbarvand","year":"2015","journal-title":"Cornea"},{"issue":"11","key":"10.1016\/j.jtos.2017.05.009_bib48","doi-asserted-by":"crossref","first-page":"6612","DOI":"10.1167\/iovs.15-16560","article-title":"Contralateral clinically unaffected eyes of patients with unilateral infectious keratitis demonstrate a sympathetic immune response","volume":"56","author":"Cruzat","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"10.1016\/j.jtos.2017.05.009_bib49","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3109\/02713683.2012.674609","article-title":"Randomized double-blind clinical trial of autologous serum versus artificial tears in dry eye syndrome","volume":"37","author":"Urzua","year":"2012","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jtos.2017.05.009_bib50","unstructured":"Lemp MA, Sullivan BD. Bilaterality in dry eye disease: implications for clinical trials. In: S DA, editor. 8th international conference on the tear film & ocular surface: basic science and clinical relevance. Montpelier, France; 2016. Abstract #45."},{"issue":"2","key":"10.1016\/j.jtos.2017.05.009_bib51","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/aos.12012","article-title":"Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implications","volume":"92","author":"Sullivan","year":"2014","journal-title":"Acta Ophthalmol"},{"issue":"2 Suppl","key":"10.1016\/j.jtos.2017.05.009_bib52","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jtos.2014.02.002","article-title":"Rethinking dry eye disease: a perspective on clinical implications","volume":"12","author":"Bron","year":"2014","journal-title":"Ocul Surf"},{"issue":"12","key":"10.1016\/j.jtos.2017.05.009_bib53","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1001\/jamaophthalmol.2015.3854","article-title":"Progressively increased variation in tear osmolarity mirrors dry eye severity","volume":"133","author":"Sullivan","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.jtos.2017.05.009_bib54","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ajo.2013.10.020","article-title":"The value of tear osmolarity as a metric in evaluating the response to dry eye therapy in the clinic and in clinical trials","volume":"157","author":"Pepose","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.jtos.2017.05.009_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/archopht.1973.01000040003001","article-title":"Shall we count numbers of eyes or numbers of subjects?","volume":"89","author":"Ederer","year":"1973","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jtos.2017.05.009_bib56","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","article-title":"TFOS DEWS II Diagnostic Methodology report","volume":"15","author":"Wolffsohn","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2017.05.009_bib57","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1001\/jama.1937.02780260001001","article-title":"The xanthines (theobromine and aminophylline) in the treatment of cardiac pain","volume":"108","author":"Gold","year":"1937","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jtos.2017.05.009_bib58","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0009-9236(99)70047-0","article-title":"Clinical pharmacology: the scientific basis of therapeutics","volume":"66","author":"Reidenberg","year":"1999","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jtos.2017.05.009_bib59","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S1542-0124(12)70004-6","article-title":"Challenges and pitfalls in clinical trials of treatments for dry eye","volume":"1","author":"Foulks","year":"2003","journal-title":"Ocul Surf"},{"issue":"4","key":"10.1016\/j.jtos.2017.05.009_bib60","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.jtos.2017.05.009_bib61","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.ophtha.2012.12.022","article-title":"A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye","volume":"120","author":"Kinoshita","year":"2013","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.jtos.2017.05.009_bib62","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.ophtha.2015.08.001","article-title":"Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study","volume":"122","author":"Tauber","year":"2015","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.jtos.2017.05.009_bib63","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jtos.2013.05.002","article-title":"Statistical approaches to assessing single and multiple outcome measures in dry eye therapy and diagnosis","volume":"11","author":"Tomlinson","year":"2013","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.jtos.2017.05.009_bib64","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jtos.2013.02.002","article-title":"Dry eye disease treatment: a systematic review of published trials and a critical appraisal of therapeutic strategies","volume":"11","author":"Alves","year":"2013","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.jtos.2017.05.009_bib65","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1542-0124(12)70311-7","article-title":"Regression to the mean","volume":"7","author":"Novack","year":"2009","journal-title":"Ocul Surf"},{"issue":"4","key":"10.1016\/j.jtos.2017.05.009_bib66","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/sim.4780020401","article-title":"How much of the placebo 'effect' is really statistical regression?","volume":"2","author":"McDonald","year":"1983","journal-title":"Stat Med"},{"issue":"7","key":"10.1016\/j.jtos.2017.05.009_bib67","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.ophtha.2015.02.037","article-title":"Comparison of two questionnaires for dry eye symptom assessment: the ocular surface disease index and the symptom assessment in dry eye","volume":"122","author":"Amparo","year":"2015","journal-title":"Ophthalmology"},{"issue":"7256","key":"10.1016\/j.jtos.2017.05.009_bib68","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/bmj.321.7256.255","article-title":"Which clinical studies provide the best evidence? The best RCT still trumps the best observational study","volume":"321","author":"Barton","year":"2000","journal-title":"Br Med J"},{"issue":"1","key":"10.1016\/j.jtos.2017.05.009_bib69","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ophtha.2015.09.029","article-title":"Topical fluorometholone protects the ocular surface of dry eye patients from desiccating stress","volume":"123","author":"Pinto-Fraga","year":"2016","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.jtos.2017.05.009_bib70","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.ophtha.2013.04.006","article-title":"Short-term consumption of oral omega-3 and dry eye syndrome","volume":"120","author":"Kangari","year":"2013","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.jtos.2017.05.009_bib71","first-page":"CD003974","article-title":"Placebo interventions for all clinical conditions","author":"Hr\u00f3bjartsson","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.jtos.2017.05.009_bib72","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0896-1549(02)00105-0","article-title":"The evolving treatment of dry eye","volume":"16","author":"Foulks","year":"2003","journal-title":"Ophthalmol Clin N Am"},{"issue":"1","key":"10.1016\/j.jtos.2017.05.009_bib73","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000309870","article-title":"Effect of changing medication regimens in glaucoma patients","volume":"196","author":"Novack","year":"1988","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jtos.2017.05.009_bib74","series-title":"Psychology in industrial organizations","author":"Maier","year":"1982"},{"issue":"4","key":"10.1016\/j.jtos.2017.05.009_bib75","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0002-9394(14)71856-2","article-title":"Topical fibronectin in the treatment of keratoconjunctivitis sicca","volume":"114","author":"Nelson","year":"1992","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.jtos.2017.05.009_bib76","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.ophtha.2012.04.010","article-title":"Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial","volume":"119","author":"Matsumoto","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2017.05.009_bib77","first-page":"877","article-title":"Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE\u2122) model","volume":"9","author":"Sosne","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2017.05.009_bib78","first-page":"34","article-title":"Thymosin B4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial","author":"Sosne","year":"2015","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.jtos.2017.05.009_bib79","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0031-1298595","article-title":"Assessing bias: the importance of considering confounding","volume":"3","author":"Skelly","year":"2012","journal-title":"Evid Based Spine Care J"},{"issue":"4","key":"10.1016\/j.jtos.2017.05.009_bib80","first-page":"221","article-title":"Report of the national eye institute\/industry workshop on clinical trials in dry eyes","volume":"21","author":"Lemp","year":"1995","journal-title":"CLAO J"},{"key":"10.1016\/j.jtos.2017.05.009_bib81","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3109\/02713683.2014.975368","article-title":"Sex, eyes, and vision: male\/female distinctions in ophthalmic disorders","volume":"40","author":"Eisner","year":"2015","journal-title":"Curr Eye Res"},{"issue":"6","key":"10.1016\/j.jtos.2017.05.009_bib82","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archophthalmol.2009.103","article-title":"Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies","volume":"127","author":"Schaumberg","year":"2009","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.jtos.2017.05.009_bib83","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.clae.2006.12.002","article-title":"Incomplete blinking: exposure keratopathy, lid wiper epitheliopathy, dry eye, refractive surgery, and dry contact lenses","volume":"30","author":"McMonnies","year":"2007","journal-title":"Contact Lens Anter Eye"},{"key":"10.1016\/j.jtos.2017.05.009_bib84","article-title":"Modification of meibomian gland lipids by topical azithromycin","volume":"50","author":"Foulks","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.jtos.2017.05.009_bib85","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1167\/iovs.10-6997e","article-title":"The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD","volume":"52","author":"Schaumberg","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"10.1016\/j.jtos.2017.05.009_bib86","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3109\/02713683.2014.987871","article-title":"Signs and symptoms of dry eye in keratoconus patients: a pilot study","volume":"40","author":"Carracedo","year":"2015","journal-title":"Curr Eye Res"},{"issue":"3","key":"10.1016\/j.jtos.2017.05.009_bib87","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3928\/1081-597X-20040501-06","article-title":"Recovery of corneal sensitivity to mechanical and chemical stimulation after laser in situ keratomileusis","volume":"20","author":"Gallar","year":"2004","journal-title":"J Refract Surg"},{"issue":"4","key":"10.1016\/j.jtos.2017.05.009_bib88","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ophtha.2014.11.006","article-title":"Effects of corneal nerve density on the response to treatment in dry eye disease","volume":"122","author":"Kheirkhah","year":"2015","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.jtos.2017.05.009_bib89","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jtos.2012.12.002","article-title":"Dry eye disease and microbial keratitis: is there a connection?","volume":"11","author":"Narayanan","year":"2013","journal-title":"Ocul Surf"},{"issue":"6 Suppl","key":"10.1016\/j.jtos.2017.05.009_bib90","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1590\/S0004-27492008000700010","article-title":"Autologous serum for ocular surface diseases","volume":"71","author":"Quinto","year":"2008","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.jtos.2017.05.009_bib91","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jtos.2017.05.004","article-title":"TFOS DEWS II Iatrogenic report","volume":"15","author":"Gomes","year":"2017","journal-title":"Ocul Surf"},{"issue":"12","key":"10.1016\/j.jtos.2017.05.009_bib92","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1097\/OPX.0000000000000420","article-title":"Clinical and biochemical tear lipid parameters in contact lens wearers","volume":"91","author":"Rohit","year":"2014","journal-title":"Optom Vis Sci"},{"issue":"2","key":"10.1016\/j.jtos.2017.05.009_bib93","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ajo.2015.05.013","article-title":"Punctal plug retention rates for the treatment of moderate to severe dry eye: a randomized, double-masked, controlled clinical trial","volume":"160","author":"Brissette","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2017.05.009_bib94","doi-asserted-by":"crossref","first-page":"TFOS20","DOI":"10.1167\/iovs.13-13125","article-title":"The TFOS international workshop on contact lens discomfort: report of the subcommittee on Epidemiology","volume":"54","author":"Dumbleton","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2017.05.009_bib95","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1192\/bjp.129.6.513","article-title":"Treatment adherence","volume":"129","author":"Blackwell","year":"1976","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jtos.2017.05.009_bib96","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev-pharmtox-011711-113247","article-title":"Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories","volume":"52","author":"Blaschke","year":"2011","journal-title":"Ann Rev Pharm Toxicol"},{"issue":"6","key":"10.1016\/j.jtos.2017.05.009_bib97","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/archophthalmol.2009.96","article-title":"An objective evaluation of eyedrop instillation in patients with glaucoma","volume":"127","author":"Stone","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jtos.2017.05.009_bib98","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1542-0124(12)70063-0","article-title":"Pipeline: thoughts generated by the annual meeting of the american society of clinical pharmacology and therapeutics","volume":"2","author":"Novack","year":"2004","journal-title":"Ocul Surf"},{"issue":"4","key":"10.1016\/j.jtos.2017.05.009_bib99","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ajo.2007.06.012","article-title":"Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use","volume":"144","author":"Robin","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.jtos.2017.05.009_bib100","first-page":"345","article-title":"Practical tips for surgical research: blinding: who, what, when, why, how?","volume":"53","author":"Karanicolas","year":"2010","journal-title":"Can J Surg"},{"key":"10.1016\/j.jtos.2017.05.009_bib101","article-title":"Clinical investigation of medical devices for human subjects - good clinical practice","author":"Standardisation IOf","year":"2011","journal-title":"Int Organ Stand"},{"issue":"3","key":"10.1016\/j.jtos.2017.05.009_bib102","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/IOP.0b013e3181b8c3ad","article-title":"Labial salivary gland transplantation for severe dry eye due to chemical burns and Stevens-Johnson syndrome","volume":"26","author":"Marinho","year":"2010","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.jtos.2017.05.009_bib103","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/ICL.0b013e3181db352f","article-title":"Improved signs, symptoms, and quality of life associated with dry eye syndrome: hydroxypropyl cellulose ophthalmic insert patient registry","volume":"36","author":"Koffler","year":"2010","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.jtos.2017.05.009_bib104","doi-asserted-by":"crossref","first-page":"E1035","DOI":"10.1097\/OPX.0b013e31825c3479","article-title":"A comparison of an eyelid-warming device to traditional compress therapy","volume":"89","author":"Pult","year":"2012","journal-title":"Optom Vis Sci"},{"issue":"5","key":"10.1016\/j.jtos.2017.05.009_bib105","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.clae.2013.02.009","article-title":"Evaluation of the ocular tolerance of a novel eyelid-warming device used for meibomian gland dysfunction","volume":"36","author":"Purslow","year":"2013","journal-title":"Contact Lens Anter Eye"},{"key":"10.1016\/j.jtos.2017.05.009_bib106","first-page":"2019","article-title":"Evaluation of the efficacy, safety, and acceptability of an eyelid warming device for the treatment of meibomian gland dysfunction","volume":"8","author":"Benitez Del Castillo","year":"2014","journal-title":"Clin Ophthalmol"},{"issue":"12","key":"10.1016\/j.jtos.2017.05.009_bib107","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1097\/ICO.0000000000000273","article-title":"Six-month effects of a thermodynamic treatment for MGD and implications of meibomian gland atrophy","volume":"33","author":"Finis","year":"2014","journal-title":"Cornea"},{"issue":"1\u20132","key":"10.1016\/j.jtos.2017.05.009_bib108","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40123-014-0025-8","article-title":"A randomized, controlled treatment trial of eyelid-warming therapies in meibomian gland dysfunction","volume":"3","author":"Sim","year":"2014","journal-title":"Ophthalmol Ther"},{"issue":"10","key":"10.1016\/j.jtos.2017.05.009_bib109","doi-asserted-by":"crossref","first-page":"e0139761","DOI":"10.1371\/journal.pone.0139761","article-title":"Clinical effect of antioxidant glasses containing extracts of medicinal plants in patients with dry eye disease: a multi-center, prospective, randomized, double-blind, placebo-controlled trial","volume":"10","author":"Choi","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.jtos.2017.05.009_bib110","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1097\/OPX.0000000000000675","article-title":"All warm compresses are not equally efficacious","volume":"92","author":"Murakami","year":"2015","journal-title":"Optom Vis Sci"},{"issue":"1","key":"10.1016\/j.jtos.2017.05.009_bib111","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1089\/pho.2014.3819","article-title":"Intense pulsed light treatment for dry eye disease due to meibomian gland dysfunction; a 3-year retrospective study","volume":"33","author":"Toyos","year":"2015","journal-title":"Photomed Laser Surg"},{"issue":"3","key":"10.1016\/j.jtos.2017.05.009_bib112","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10792-014-9947-3","article-title":"Evaluation of a novel eyelid-warming device in meibomian gland dysfunction unresponsive to traditional warm compress treatment: an in vivo confocal study","volume":"35","author":"Villani","year":"2015","journal-title":"Int Ophthalmol"},{"issue":"9","key":"10.1016\/j.jtos.2017.05.009_bib113","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1097\/OPX.0000000000000601","article-title":"Comparison of self-applied heat therapy for meibomian gland dysfunction","volume":"92","author":"Wang","year":"2015","journal-title":"Optom Vis Sci"},{"issue":"6","key":"10.1016\/j.jtos.2017.05.009_bib114","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.clae.2015.06.002","article-title":"Temperature profiles of patient-applied eyelid warming therapies","volume":"38","author":"Wang","year":"2015","journal-title":"Contact Lens Anter Eye"},{"issue":"2","key":"10.1016\/j.jtos.2017.05.009_bib115","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/ICL.0000000000000166","article-title":"Long-term (3 Year) effects of a single thermal pulsation system treatment on meibomian gland function and dry eye symptoms","volume":"42","author":"Greiner","year":"2016","journal-title":"Eye Contact Lens"},{"issue":"6","key":"10.1016\/j.jtos.2017.05.009_bib116","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/ICL.0000000000000228","article-title":"Clinical trial of thermal pulsation (LipiFlow) in meibomian gland dysfunction with preteatment meibography","volume":"42","author":"Zhao","year":"2016","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.jtos.2017.05.009_bib117","first-page":"795","article-title":"A nonrandomized, open-label study to evaluate the effect of nasal stimulation on tear production in subjects with dry eye disease","volume":"10","author":"Friedman","year":"2016","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"10.1016\/j.jtos.2017.05.009_bib118","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1542-0124(11)70010-6","article-title":"The development of drugs vs devices","volume":"9","author":"Novack","year":"2011","journal-title":"Ocul Surf"},{"issue":"5","key":"10.1016\/j.jtos.2017.05.009_bib119","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.spinee.2007.01.008","article-title":"Understanding the minimum clinically important difference: a review of concepts and methods","volume":"7","author":"Copay","year":"2007","journal-title":"Spine J"},{"issue":"4","key":"10.1016\/j.jtos.2017.05.009_bib120","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","article-title":"Measurement of health status. Ascertaining the minimal clinically important difference","volume":"10","author":"Jaeschke","year":"1989","journal-title":"Control Clin Trials"},{"issue":"11","key":"10.1016\/j.jtos.2017.05.009_bib121","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/ptj\/78.11.1186","article-title":"Sensitivity to change of the Roland-morris back pain questionnaire: part 1","volume":"78","author":"Stratford","year":"1998","journal-title":"Phys Ther"},{"issue":"8","key":"10.1016\/j.jtos.2017.05.009_bib122","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/01.ico.0000133997.07144.9e","article-title":"The lack of association between signs and symptoms in patients with dry eye disease","volume":"23","author":"Nichols","year":"2004","journal-title":"Cornea"},{"issue":"8","key":"10.1016\/j.jtos.2017.05.009_bib123","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/01.ico.0000214802.40313.fa","article-title":"Dysfunctional tear syndrome: a Delphi approach to treatment recommendations","volume":"25","author":"Behrens","year":"2006","journal-title":"Cornea"},{"issue":"5","key":"10.1016\/j.jtos.2017.05.009_bib124","first-page":"75","article-title":"The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye WorkShop","volume":"2007","year":"2007","journal-title":"Ocul Surf"},{"issue":"1","key":"10.1016\/j.jtos.2017.05.009_bib125","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jtos.2013.10.002","article-title":"Challenges in using signs and symptoms to evaluate new biomarkers of dry eye disease","volume":"12","author":"Sullivan","year":"2014","journal-title":"Ocul Surf"},{"issue":"9","key":"10.1016\/j.jtos.2017.05.009_bib126","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1167\/iovs.09-4596","article-title":"Tear osmolarity as a biomarker for dry eye disease severity","volume":"51","author":"Suzuki","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.jtos.2017.05.009_bib127","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.ophtha.2012.03.017","article-title":"Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease","volume":"119","author":"Huang","year":"2012","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.jtos.2017.05.009_bib128","doi-asserted-by":"crossref","first-page":"6280","DOI":"10.1167\/iovs.13-12150","article-title":"Comparison of two methods for composite score generation in dry eye syndrome","volume":"54","author":"See","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2017.05.009_bib129","article-title":"Diagnostic performance of osmolarity combined with subset markers of dry eye disease in an unstratified patient population","volume":"51","author":"Sullivan","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.jtos.2017.05.009_bib130","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5301\/ejo.5000779","article-title":"Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial","volume":"26","author":"Leonardi","year":"2016","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jtos.2017.05.009_bib131","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jtos.2017.03.006","article-title":"TFOS DEWS II Tear Film report","volume":"15","author":"Willcox","year":"2017","journal-title":"Ocul Surf"},{"issue":"11","key":"10.1016\/j.jtos.2017.05.009_bib132","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1167\/iovs.16-19757","article-title":"Tear interferon-gamma as a biomarker for evaporative dry eye disease","volume":"57","author":"Jackson","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"10.1016\/j.jtos.2017.05.009_bib133","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/bjophthalmol-2013-304619","article-title":"Diagnosing the severity of dry eye: a clear and practical algorithm","volume":"98","author":"Baudouin","year":"2014","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"10.1016\/j.jtos.2017.05.009_bib134","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/OPX.0b013e3181ff99ab","article-title":"Temporal stability in the perception of dry eye ocular discomfort symptoms","volume":"87","author":"Cardona","year":"2010","journal-title":"Optom Vis Sci"},{"issue":"6","key":"10.1016\/j.jtos.2017.05.009_bib135","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.clae.2013.06.001","article-title":"Ethnic differences in dry eye symptoms: effects of corneal staining and length of contact lens wear","volume":"36","author":"Tran","year":"2013","journal-title":"Contact Lens Anter Eye"},{"issue":"2","key":"10.1016\/j.jtos.2017.05.009_bib136","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0002-9394(03)00218-6","article-title":"Prevalence of dry eye syndrome among US women","volume":"136","author":"Schaumberg","year":"2003","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.jtos.2017.05.009_bib137","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s11882-004-0077-2","article-title":"Dry eye: diagnosis and current treatment strategies","volume":"4","author":"O'Brien","year":"2004","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jtos.2017.05.009_bib138","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/archophthalmol.2009.356","article-title":"Minimal clinically important difference for the ocular surface disease index","volume":"128","author":"Miller","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jtos.2017.05.009_bib139","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1477-7525-2-44","article-title":"Comparison of the NEI-VFQ and OSDI questionnaires in patients with Sj\u00f6gren's syndrome-related dry eye","volume":"2","author":"Vitale","year":"2004","journal-title":"Health Qual Life Outcomes"},{"issue":"7","key":"10.1016\/j.jtos.2017.05.009_bib140","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/00003226-200210000-00007","article-title":"Use of the dry eye questionnaire to measure symptoms of ocular irritation in patients with aqueous tear deficient dry eye","volume":"21","author":"Begley","year":"2002","journal-title":"Cornea"},{"issue":"2","key":"10.1016\/j.jtos.2017.05.009_bib141","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/ICO.0000000000000038","article-title":"A review of quality of life measures in dry eye questionnaires","volume":"33","author":"Grubbs","year":"2014","journal-title":"Cornea"},{"issue":"5","key":"10.1016\/j.jtos.2017.05.009_bib142","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the ocular surface disease index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.jtos.2017.05.009_bib143","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S1542-0124(12)70053-8","article-title":"Development and validation of a short global dry eye symptom index","volume":"5","author":"Schaumberg","year":"2007","journal-title":"Ocul Surf"},{"issue":"1","key":"10.1016\/j.jtos.2017.05.009_bib144","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1542-0124(11)70009-X","article-title":"Impaired visual performance in patients with dry eye","volume":"9","author":"Ridder","year":"2011","journal-title":"Ocul Surf"},{"issue":"2","key":"10.1016\/j.jtos.2017.05.009_bib145","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1524-4733.2005.03074.x","article-title":"Comparing the discriminative validity of two generic and one disease-specific health-related quality of life measures in a sample of patients with dry eye","volume":"8","author":"Rajagopalan","year":"2005","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jtos.2017.05.009_bib146","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/00003226-199807000-00006","article-title":"Low spatial-contrast sensitivity in dry eyes","volume":"17","author":"Rolando","year":"1998","journal-title":"Cornea"},{"issue":"4","key":"10.1016\/j.jtos.2017.05.009_bib147","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1600-0420.2006.00671.x","article-title":"Contrast sensitivity and disability glare in patients with dry eye","volume":"84","author":"Puell","year":"2006","journal-title":"Acta Ophthalmol Scand"},{"issue":"10","key":"10.1016\/j.jtos.2017.05.009_bib148","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/S0161-6420(02)01136-3","article-title":"Effect of artificial tears on corneal surface regularity, contrast sensitivity, and glare disability in dry eyes","volume":"109","author":"Huang","year":"2002","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.jtos.2017.05.009_bib149","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/OPX.0b013e3182780dbb","article-title":"Evaluation of reading speed and contrast sensitivity in dry eye disease","volume":"90","author":"Ridder","year":"2013","journal-title":"Optom Vis Sci"},{"issue":"2","key":"10.1016\/j.jtos.2017.05.009_bib150","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0002-9394(01)01365-4","article-title":"Impaired functional visual acuity of dry eye patients","volume":"133","author":"Goto","year":"2002","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.jtos.2017.05.009_bib151","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ajo.2004.08.075","article-title":"The application of a new continuous functional visual acuity measurement system in dry eye syndromes","volume":"139","author":"Ishida","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.jtos.2017.05.009_bib152","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.ophtha.2012.03.004","article-title":"Tear film aberration dynamics and vision-related quality of life in patients with dry eye disease","volume":"119","author":"Denoyer","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2017.05.009_bib153","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jtos.2017.05.009_bib154","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13167-016-0065-3","article-title":"Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine","volume":"7","author":"Hagan","year":"2016","journal-title":"EPMA J"},{"key":"10.1016\/j.jtos.2017.05.009_bib155","doi-asserted-by":"crossref","first-page":"157","DOI":"10.17925\/EOR.2012.06.03.157","article-title":"Biomarkers in dry eye disease","volume":"6","author":"Lemp","year":"2012","journal-title":"Eur Ophthalmic Rev"},{"issue":"11","key":"10.1016\/j.jtos.2017.05.009_bib156","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.1021\/pr900686s","article-title":"Identification of tear fluid biomarkers in dry eye syndrome using iTRAQ quantitative proteomics","volume":"8","author":"Zhou","year":"2009","journal-title":"J Proteom Res"},{"issue":"9","key":"10.1016\/j.jtos.2017.05.009_bib157","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/ICO.0b013e3181a16578","article-title":"Analysis of inflammatory cytokines in the tears of dry eye patients","volume":"28","author":"Massingale","year":"2009","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2017.05.009_bib158","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.exer.2013.03.018","article-title":"HLA-DR expression as a biomarker of inflammation for multicenter clinical trials of ocular surface disease","volume":"111","author":"Epstein","year":"2013","journal-title":"Exp Eye Res"},{"issue":"13","key":"10.1016\/j.jtos.2017.05.009_bib159","doi-asserted-by":"crossref","first-page":"8327","DOI":"10.1167\/iovs.13-12132","article-title":"Tear cytokine profile as a noninvasive biomarker of inflammation for ocular surface diseases: standard operating procedures","volume":"54","author":"Wei","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2017.05.009_bib160","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2147\/OPTH.S92653","article-title":"Does the type of treatment have an influence on utility values in a glaucoma population?","volume":"9","author":"Paletta Guedes","year":"2015","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"10.1016\/j.jtos.2017.05.009_bib161","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1167\/iovs.04-1426","article-title":"Decreased corneal sensitivity in patients with dry eye","volume":"46","author":"Bourcier","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2017.05.009_bib162","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtos.2017.05.002","article-title":"TFOS DEWS II Pain and Sensation report","volume":"15","author":"Belmonte","year":"2017","journal-title":"Ocul Surf"},{"issue":"1","key":"10.1016\/j.jtos.2017.05.009_bib163","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/bjophthalmol-2014-306280","article-title":"Ocular neuropathic pain","volume":"100","author":"Rosenthal","year":"2016","journal-title":"Br J Ophthalmol"},{"issue":"8 Suppl","key":"10.1016\/j.jtos.2017.05.009_bib164","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/01.ico.0000136685.88489.70","article-title":"Tear film stability analysis system: introducing a new application for videokeratography","volume":"23","author":"Goto","year":"2004","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2017.05.009_bib165","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.2147\/OPTH.S95242","article-title":"Tear film osmolarity and dry eye disease: a review of the literature","volume":"9","author":"Potvin","year":"2015","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"10.1016\/j.jtos.2017.05.009_bib166","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/archopht.1990.01070030090035","article-title":"Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis","volume":"108","author":"Abelson","year":"1990","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.jtos.2017.05.009_bib167","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1542-0124(12)70196-9","article-title":"Methodologies for the study of ocular surface disease","volume":"3","author":"Ousler","year":"2005","journal-title":"Ocul Surf"},{"issue":"12","key":"10.1016\/j.jtos.2017.05.009_bib168","doi-asserted-by":"crossref","first-page":"8811","DOI":"10.1167\/iovs.10-6841","article-title":"Effect of controlled adverse chamber environment exposure on tear functions in silicon hydrogel and hydrogel soft contact lens wearers","volume":"52","author":"Kojima","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2017.05.009_bib169","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2147\/OPTH.S44688","article-title":"Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye","volume":"7","author":"Meerovitch","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2017.05.009_bib170","first-page":"633","article-title":"Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: results of a randomized clinical trial","volume":"5","author":"Patane","year":"2011","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"10.1016\/j.jtos.2017.05.009_bib171","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ajo.2011.11.003","article-title":"A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye","volume":"153","author":"Semba","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2017.05.009_bib172","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/tvst.2.6.1","article-title":"Translating drugs from animals to humans: do we need to prove efficacy?","volume":"2","author":"Novack","year":"2013","journal-title":"Transl Vis Sci Technol"},{"issue":"6","key":"10.1016\/j.jtos.2017.05.009_bib173","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/BF01059556","article-title":"Ocular and systemic bioavailability of ophthalmic flurbiprofen","volume":"12","author":"Tang-Liu","year":"1984","journal-title":"J Pharmacokinet Biopharm"},{"issue":"1","key":"10.1016\/j.jtos.2017.05.009_bib174","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/jop.2015.0120","article-title":"How much nonclinical safety data are required for a clinical study in ophthalmology?","volume":"32","author":"Novack","year":"2016","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jtos.2017.05.009_bib175","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1001\/jama.1995.03530200047035","article-title":"Pharmacogenetic explanation for excessive b-blockade following timolol eye drops: potential for oral-ophthalmic drug interaction","volume":"274","author":"Edeki","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.jtos.2017.05.009_bib176","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/jop.2015.1504","article-title":"The \u201cT\u201d in JOPT","volume":"31","author":"Novack","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jtos.2017.05.009_bib177","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11095-007-9434-x","article-title":"Bioequivalence approaches for highly variable drugs and drug products","volume":"25","author":"Haidar","year":"2008","journal-title":"Pharm Res"},{"issue":"10","key":"10.1016\/j.jtos.2017.05.009_bib178","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1345\/aph.1M141","article-title":"Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration","volume":"43","author":"Davit","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.jtos.2017.05.009_bib179","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/clpt.2011.337","article-title":"Evidence vs. access: can twenty-first-century drug regulation refine the tradeoffs?","volume":"91","author":"Woodcock","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jtos.2017.05.009_bib180","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/clpt.2010.251","article-title":"A concise display of multiple end points for benefit-risk assessment","volume":"89","author":"Levitan","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jtos.2017.05.009_bib181","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/clpt.2009.71","article-title":"The clinical utility index as a practical multiattribute approach to drug development decisions","volume":"86","author":"Poland","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jtos.2017.05.009_bib182","article-title":"Transparent trade-offs","author":"Korsan","year":"2005","journal-title":"Pharm Exec"},{"issue":"2","key":"10.1016\/j.jtos.2017.05.009_bib183","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/clpt.2011.197","article-title":"A novel metric to assess the clinical utility of a drug in the presence of efficacy and dropout information","volume":"91","author":"Goyal","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jtos.2017.05.009_bib184","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jtos.2012.08.003","article-title":"The benefit\/risk of good therapeutics","volume":"10","author":"Novack","year":"2012","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.jtos.2017.05.009_bib185","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1542-0124(12)70141-6","article-title":"Decoding the packaging insert: indications","volume":"1","author":"Novack","year":"2003","journal-title":"Ocul Surf"},{"issue":"5557","key":"10.1016\/j.jtos.2017.05.009_bib186","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1126\/science.295.5557.1086","article-title":"Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule","volume":"295","author":"Gadek","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.jtos.2017.05.009_bib187","series-title":"Assessment report: Ikervis","author":"Anonymous","year":"2016"},{"issue":"12","key":"10.1016\/j.jtos.2017.05.009_bib188","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.ophtha.2012.06.052","article-title":"Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study","volume":"119","author":"Kinoshita","year":"2012","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.jtos.2017.05.009_bib189","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.ophtha.2012.12.022","article-title":"A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye","volume":"120","author":"Kinoshita","year":"2013","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.jtos.2017.05.009_bib190","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3109\/02713683.2011.631721","article-title":"A single LipiFlow\u00ae Thermal Pulsation System treatment improves meibomian gland function and reduces dry eye symptoms for 9 months","volume":"37","author":"Greiner","year":"2012","journal-title":"Curr Eye Res"},{"issue":"2","key":"10.1016\/j.jtos.2017.05.009_bib191","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jtos.2013.12.001","article-title":"Evaluation of an automated thermodynamic treatment (LipiFlow\u00ae) system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial","volume":"12","author":"Finis","year":"2014","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2017.05.009_bib192","series-title":"De novo classification request for TearScience, Inc. Lipiflox(R) thermal pulsation system","author":"Anonymous","year":"2010"},{"key":"10.1016\/j.jtos.2017.05.009_bib193","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ajo.2017.03.002","article-title":"Randomized controlled crossover trial comparing the impact of sham or intranasal tear neurostimulation on conjunctival goblet cell degranulation","volume":"177","author":"Gumus","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2017.05.009_bib194","unstructured":"513(f)(2) - Evaluation of automatic class III designation, guidance for industry and CDRH staff. In: Evaluation OoD, editor. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, FDA, Center for Devices and Radiological Health, Rockville, MD 208501998."},{"key":"10.1016\/j.jtos.2017.05.009_bib195","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000131093","article-title":"Minor salivary gland transplantation","volume":"41","author":"Geerling","year":"2008","journal-title":"Dev Ophthalmol"},{"key":"10.1016\/j.jtos.2017.05.009_bib196","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000131094","article-title":"Transplantation of the major salivary glands","volume":"41","author":"Geerling","year":"2008","journal-title":"Dev Ophthalmol"},{"key":"10.1016\/j.jtos.2017.05.009_bib197","series-title":"Statistical principles for clinical trials (E9)","author":"International Conference on Harmonisation","year":"1998"},{"issue":"1","key":"10.1016\/j.jtos.2017.05.009_bib198","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ajo.2015.03.018","article-title":"The Importance of A Priori statistical planning in controlled clinical trials","volume":"160","author":"Novack","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2017.05.009_bib199","series-title":"Multiple testing problems in pharmaceutical statistics","first-page":"1","article-title":"Multiplicity problems in clinical trials: a regulatory perspective","author":"Huque","year":"2010"},{"issue":"1","key":"10.1016\/j.jtos.2017.05.009_bib200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ophtha.2005.09.015","article-title":"The state of being noninferior","volume":"113","author":"Musch","year":"2006","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.jtos.2017.05.009_bib201","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jtos.2014.01.003","article-title":"Some are more equal than others","volume":"12","author":"Novack","year":"2014","journal-title":"Ocul Surf"},{"issue":"5","key":"10.1016\/j.jtos.2017.05.009_bib202","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0039-6257(87)90116-0","article-title":"Ophthalmic beta-blockers since timolol","volume":"31","author":"Novack","year":"1987","journal-title":"Surv Ophthalmol"},{"issue":"7","key":"10.1016\/j.jtos.2017.05.009_bib203","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ophtha.2009.11.029","article-title":"Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial","volume":"117","author":"Avni","year":"2010","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.jtos.2017.05.009_bib204","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/ICO.0000000000000325","article-title":"Prospective evaluation of hypromellose 2% for punctal occlusion in patients with dry eye","volume":"34","author":"Capita","year":"2015","journal-title":"Cornea"},{"issue":"4","key":"10.1016\/j.jtos.2017.05.009_bib205","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.clinthera.2015.01.001","article-title":"Efficacy, safety, and acceptability of a lipid-based artificial tear formulation: a randomized, controlled, multicenter clinical trial","volume":"37","author":"Simmons","year":"2015","journal-title":"Clin Ther"},{"issue":"8","key":"10.1016\/j.jtos.2017.05.009_bib206","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1089\/jop.2015.0048","article-title":"Semifluorinated alkane eye drops for treatment of dry eye disease-a prospective, multicenter noninterventional study","volume":"31","author":"Steven","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jtos.2017.05.009_bib207","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ophtha.2013.09.015","article-title":"Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study","volume":"121","author":"Sheppard","year":"2014","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.jtos.2017.05.009_bib208","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1136\/bjo.79.11.1007","article-title":"Sodium hyaluronate eyedrops in the treatment of dry eyes","volume":"79","author":"Shimmura","year":"1995","journal-title":"Br J Ophthalmol"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012417301180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012417301180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T02:14:43Z","timestamp":1602555283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012417301180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":208,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S1542012417301180"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2017.05.009","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TFOS DEWS II Clinical Trial Design Report","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2017.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}